BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 17082512)

  • 21. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw.
    Haidar A; Jønler M; Folkmar TB; Lund L
    Scand J Urol Nephrol; 2009; 43(6):442-4. PubMed ID: 19903091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
    Murad OM; Arora S; Farag AF; Guber HA
    Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
    Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
    Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.
    DE Iuliis F; Taglieri L; Amoroso L; Vendittozzi S; Blasi L; Salerno G; Lanza R; Scarpa S
    Anticancer Res; 2014 May; 34(5):2477-80. PubMed ID: 24778063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Osteonecrosis associated with the use of biphosphonates: Case report].
    Anguita C T; Agurto P J; Roa E I; Laissle C G
    Rev Med Chil; 2006 Sep; 134(9):1161-5. PubMed ID: 17171218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Scintigraphic evaluation of mandibular bone turnover in patients with solid tumors receiving zoledronic acid.
    Van den Wyngaert T; Huizing MT; Fossion E; Vermorken JB
    Oral Oncol; 2010 Mar; 46(3):214-8. PubMed ID: 20138570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphosphonates and osteonecrosis of the jaw: a case report.
    Reiriz AB; De Zorzi Pde M; Lovat CP
    Clinics (Sao Paulo); 2008 Apr; 63(2):281-4. PubMed ID: 18438586
    [No Abstract]   [Full Text] [Related]  

  • 28. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
    Wutzl A; Eisenmenger G; Hoffmann M; Czerny C; Moser D; Pietschmann P; Ewers R; Baumann A
    Wien Klin Wochenschr; 2006 Aug; 118(15-16):473-8. PubMed ID: 16957978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Avascular osteonecrosis of the jaws induced by diphosphonates].
    Lannoy D; Decaudin B; Barrier F; Bemba M; Wierre L; Pignon JM; Horrent S; Résibois JP; Wetterwald M; Odou P
    Therapie; 2006; 61(4):363-5. PubMed ID: 17124954
    [No Abstract]   [Full Text] [Related]  

  • 32. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
    Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
    Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).
    Rathbone EJ; Brown JE; Marshall HC; Collinson M; Liversedge V; Murden GA; Cameron D; Bell R; Spensley S; Agrawal R; Jyothirmayi R; Chakraborti P; Yuille F; Coleman RE
    J Clin Oncol; 2013 Jul; 31(21):2685-91. PubMed ID: 23796998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases.
    Junquera L; Gallego L; Cuesta P; Pelaz A; de Vicente JC
    Am J Otolaryngol; 2009; 30(6):390-5. PubMed ID: 19880027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
    Hoefert S; Schmitz I; Tannapfel A; Eufinger H
    Clin Oral Investig; 2010 Jun; 14(3):271-84. PubMed ID: 19536569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
    Abu-Id MH; Warnke PH; Gottschalk J; Springer I; Wiltfang J; Acil Y; Russo PA; Kreusch T
    J Craniomaxillofac Surg; 2008 Mar; 36(2):95-103. PubMed ID: 18234504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
    Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
    Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
    Cetiner S; Sucak GT; Kahraman SA; Aki SZ; Kocakahyaoglu B; Gultekin SE; Cetiner M; Haznedar R
    J Bone Miner Metab; 2009; 27(4):435-43. PubMed ID: 19240969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects.
    Ficarra G; Beninati F
    Head Neck Pathol; 2007 Dec; 1(2):132-40. PubMed ID: 20614264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early appearance of osteonecrosis of the jaw after zoledronic acid in a patient with a long history of taking oral bisphosphonates.
    Uña E
    BMJ Case Rep; 2012 Mar; 2012():. PubMed ID: 22605820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.